Member Log In
HR3 attempts to address some of the challenges facing healthcare costs by limiting drug prices. BIO AL's Executive Director sent the following letter to Alabama's congressional representatives and senators.
I’m writing on behalf of BIO Alabama to express our concerns about HR3 and the impact it would have on innovation and on the future development of life-saving medical treatments. Reference pricing would have a negative impact on patients and on our bioscience industry in Alabama.
Like BIO at the national level, BIO Alabama is deeply concerned about this legislation. We remain committed to working with you on patient-centered reforms to improve access to medications and treatments without putting our industry — and more importantly, the next generation of cures — at risk.
As a scientist, I understand the tremendous resources required to create and safely introduce new treatments, diagnostics, and medical instruments to healthcare. In my role as Founder of The Written Science, I spent years working with early-stage innovators, fueled by their zeal and hope for better medicine in the future. I experienced the challenges of healthcare access and pricing abuse in my clinical career. The challenges facing healthcare are complex and multifaceted, but HR3 is not a satisfactory solution and will create more holes in patient treatment than it fills.
If you have questions, please do not hesitate to call me.
- Rachel Lane PhD, RD
100 Drake Dr., Unit 688Normal, AL 35762
© BIO Alabama